New affordable oral cholera vaccine receives prequalification by the World Health Organization

New affordable oral cholera vaccine receives prequalification by the World Health Organization - Oral cholera vaccine manufactured by Korean company EuBiologics following technology transfer from the International Vaccine Institute (IVI) - Vaccine developed through international public-private partnership involving IVI and EuBiologics - Euvichol will be used to protect the world’s underprivileged populations from cholera SEOUL, KOREA – EuBiologics Co., Ltd. (EuBiologics) and the International Vaccine Institute (IVI) announced today that Euvichol®, an inactivated oral cholera vaccine (OCV), recently received prequalification from the World Health Organization (WHO). Developed to protect against epidemic and endemic cholera, the two-dose oral vaccine is low-cost and ready to use in a single-dose vial, facilitating its use in mass immunization programs in low-income countries. “I am very pleased that Euvichol®, a vaccine whose development was enabled by IVI, was prequalified by WHO,” said Dr. Jerome Kim, IVI’s Director General. “This milestone shows that public-private partnerships - such as that between IVI and EuBiologics – are effective in developing vaccines against diseases of the poor like cholera.” Click the link--> http://www.ivi.int/web/www/07_03?p_p_id=EXT_BBS&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-1&p_p_col_pos=1&p_p_col_count=2&_EXT_BBS_struts_action=%2Fext%2Fbbs%2Fview_message&_EXT_BBS_sCategory=&_EXT_BBS_sSubCategory=&_EXT_BBS_sTitle=&_EXT_BBS_sWriter=&_EXT_BBS_sTag=&_EXT_BBS_sContent=&_EXT_BBS_sCategory2=&_EXT_BBS_sSubCategory2=&_EXT_BBS_sKeyType=&_EXT_BBS_sKeyword=&_EXT_BBS_curPage=1&_EXT_BBS_messageId=859

The release as fetched from its publisher. eubiologics.com ↗